{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:00:11Z","timestamp":1791216011870,"version":"4.1.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"DOI":"10.1007\/s41669-026-00682-7","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:48:32Z","timestamp":1791215312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Budget Impact Model of a Novel cfRNA Test-and-Treat Strategy for Preeclampsia in Advanced Maternal Age Pregnancies Compared with Current Guidelines"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8010-9772","authenticated-orcid":false,"given":"April","family":"Zambelli-Weiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Nathanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"issue":"12","key":"682_CR1","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1001\/jama.2021.14781","volume":"326","author":"US Preventive Services Task Force","year":"2021","unstructured":"US Preventive Services Task Force. Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force Recommendation Statement. JAMA. 2021;326(12):1186\u201391. https:\/\/doi.org\/10.1001\/jama.2021.14781.","journal-title":"JAMA"},{"issue":"3","key":"682_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ajog.2017.04.032","volume":"217","author":"W Stevens","year":"2017","unstructured":"Stevens W, et al. Short-term costs of preeclampsia to the United States health care system. Am J Obstet Gynecol. 2017;217(3):237-248.e16. https:\/\/doi.org\/10.1016\/j.ajog.2017.04.032.","journal-title":"Am J Obstet Gynecol"},{"issue":"13","key":"682_CR3","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCULATIONAHA.118.038080","volume":"140","author":"LJ Leon","year":"2019","unstructured":"Leon LJ, et al. Preeclampsia and cardiovascular disease in a large UK pregnancy cohort of linked electronic health records. Circulation. 2019;140(13):1050\u201360. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038080.","journal-title":"Circulation"},{"issue":"2","key":"682_CR4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ajog.2024.01.013","volume":"231","author":"C Carey","year":"2024","unstructured":"Carey C, et al. Hypertensive disorders of pregnancy and the risk of maternal dementia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2024;231(2):196\u2013210. https:\/\/doi.org\/10.1016\/j.ajog.2024.01.013.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"682_CR5","doi-asserted-by":"publisher","first-page":"563.e1","DOI":"10.1016\/j.ajog.2023.10.008","volume":"230","author":"C Crump","year":"2024","unstructured":"Crump C, Sundquist J, Sundquist K. Adverse pregnancy outcomes and long-term risk of chronic kidney disease in women: national cohort and co-sibling study. Am J Obstet Gynecol. 2024;230(5):563.e1-563.e20. https:\/\/doi.org\/10.1016\/j.ajog.2023.10.008.","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"682_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.26394","volume":"7","author":"F Lihme","year":"2024","unstructured":"Lihme F, Basit S, Thilaganathan B, Boyd HA. Patterns of antihypertensive medication use in the first 2 years post partum. JAMA Netw Open. 2024;7(8):e2426394. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.26394.","journal-title":"JAMA Netw Open"},{"key":"682_CR7","unstructured":"ACOG Statement on USPSTF final recommendations on screening for preeclampsia. https:\/\/www.acog.org\/en\/news\/news-releases\/2017\/04\/acog-statement-on-uspstf-final-recommendations-on-screening-for-preeclampsia. Accessed 17 Feb 2022."},{"key":"682_CR8","doi-asserted-by":"publisher","unstructured":"Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135(6), e237\u2013e260. https:\/\/doi.org\/10.1097\/AOG.0000000000003891","DOI":"10.1097\/AOG.0000000000003891"},{"issue":"6","key":"682_CR9","doi-asserted-by":"publisher","first-page":"e2317641","DOI":"10.1001\/jamanetworkopen.2023.17641","volume":"6","author":"DA Fink","year":"2008","unstructured":"Fink DA, et al. Trends in maternal mortality and severe maternal morbidity during delivery-related hospitalizations in the United States, 2008 to 2021. JAMA Netw Open. 2008;6(6):e2317641. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.17641.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"682_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.023791","volume":"11","author":"NA Cameron","year":"2022","unstructured":"Cameron NA, Everitt I, Seegmiller LE, Yee LM, Grobman WA, Khan SS. Trends in the incidence of new-onset hypertensive disorders of pregnancy among rural and urban areas in the United States, 2007 to 2019. J Am Heart Assoc. 2022;11(2):e023791. https:\/\/doi.org\/10.1161\/JAHA.121.023791.","journal-title":"J Am Heart Assoc"},{"key":"682_CR11","unstructured":"Centers for Disease Control and Prevention (CDC), National Center for Health Statistics. National vital statistics system, natality on CDC WONDER online database. 2025. http:\/\/wonder.cdc.gov\/natality-expanded-current.html."},{"key":"682_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2393-12-47","volume":"12","author":"R Lamminp\u00e4\u00e4","year":"1997","unstructured":"Lamminp\u00e4\u00e4 R, Vehvil\u00e4inen-Julkunen K, Gissler M, Heinonen S. Preeclampsia complicated by advanced maternal age: a registry-based study on primiparous women in Finland 1997-2008. BMC Pregnancy Childbirth. 1997;12:47. https:\/\/doi.org\/10.1186\/1471-2393-12-47.","journal-title":"BMC Pregnancy Childbirth"},{"key":"682_CR13","doi-asserted-by":"crossref","unstructured":"Driscoll AK, Hamilton BE. Effects of age-specific fertility trends on overall fertility trends: United States, 1990\u20132023. https:\/\/stacks.cdc.gov. Accessed 07 Oct 2025.","DOI":"10.15620\/cdc\/174576"},{"key":"682_CR14","unstructured":"Fingar KR, Mabry-Hernandez I, Ngo-Metzger Q, Wolff T, Steiner C, Elixhauser A. Delivery hospitalizations involving preeclampsia and eclampsia, 2005\u20132014. Agency for Healthcare Research and Quality (US), Rockville (MD), HCUP Statistical Brief #222, 2017."},{"issue":"4","key":"682_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3109\/10641955.2015.1090581","volume":"34","author":"S Shahul","year":"2015","unstructured":"Shahul S, et al. Racial disparities in comorbidities, complications, and maternal and fetal outcomes in women with preeclampsia\/eclampsia. Hypertens Pregnancy. 2015;34(4):506\u201315. https:\/\/doi.org\/10.3109\/10641955.2015.1090581.","journal-title":"Hypertens Pregnancy"},{"key":"682_CR16","unstructured":"The American College of Obstetricians and Gynecologists. Tailored prenatal care delivery for pregnant individuals. 2025. https:\/\/www.acog.org\/-\/media\/project\/acog\/acogorg\/clinical\/files\/clinical-consensus\/articles\/2025\/04\/tailored-prenatal-care-delivery-for-pregnant-individuals.pdf?rev=5090db51445e4f7eaccfd4b5c9de7983&hash=9A628D8A3AC996A84CE0EEE00624BD56. Accessed 28 Oct 2025."},{"key":"682_CR17","unstructured":"Blue Cross Blue Shield. Report on racial and ethnic disparities in maternal health. Blue Cross Blue Shield Association. https:\/\/www.bcbs.com\/news-and-insights\/report\/racial-and-ethnic-disparities-in-maternal-health. Accessed 07 Oct 2025."},{"key":"682_CR18","unstructured":"McElrath T, Haverty C, Rasmussen M, Lee M, Jain M. Author response to bornstein and nicolaides. https:\/\/jamanetwork-com.proxy1.library.jhu.edu\/journals\/jamanetworkopen\/fullarticle\/2836551. Accessed 21 Oct 2025."},{"issue":"7","key":"682_CR19","doi-asserted-by":"publisher","first-page":"e2521792","DOI":"10.1001\/jamanetworkopen.2025.21792","volume":"8","author":"TF McElrath","year":"2025","unstructured":"McElrath TF, et al. Utility of the US Preventive Services Task Force for preeclampsia risk assessment and aspirin prophylaxis. JAMA Netw Open. 2025;8(7):e2521792. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.21792.","journal-title":"JAMA Netw Open"},{"key":"682_CR20","doi-asserted-by":"publisher","unstructured":"ACOG Committee Opinion No. 743: low-dose aspirin use during pregnancy. Obstet Gynecol. 2018;132(1), e44\u2013e52. https:\/\/doi.org\/10.1097\/AOG.0000000000002708.","DOI":"10.1097\/AOG.0000000000002708"},{"issue":"1","key":"682_CR21","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.42343","volume":"5","author":"SM Wheeler","year":"2022","unstructured":"Wheeler SM, Myers SO, Swamy GK, Myers ER. Estimated prevalence of risk factors for preeclampsia among individuals giving birth in the US in 2019. JAMA Netw Open. 2022;5(1):e2142343. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.42343.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"682_CR22","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ajog.2023.04.031","volume":"229","author":"R Horgan","year":"2023","unstructured":"Horgan R, Hage Diab Y, Waller J, Abuhamad A, Saade G. Low-dose aspirin therapy for the prevention of preeclampsia: time to reconsider our recommendations? Am J Obstet Gynecol. 2023;229(4):410\u20138. https:\/\/doi.org\/10.1016\/j.ajog.2023.04.031.","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"682_CR23","doi-asserted-by":"publisher","DOI":"10.1097\/og9.0000000000000069","volume":"2","author":"TS Freret","year":"2025","unstructured":"Freret TS, Bryant AS, James KE, Kaimal AJ, Melamed A, Clapp MA. Changes in low-dose aspirin use after updated guidance on sociodemographic risk factors for preeclampsia. O G Open. 2025;2(2):e069. https:\/\/doi.org\/10.1097\/og9.0000000000000069.","journal-title":"O G Open"},{"issue":"2","key":"682_CR24","doi-asserted-by":"publisher","first-page":"B2","DOI":"10.1016\/j.ajog.2023.04.039","volume":"229","author":"A Combs","year":"2023","unstructured":"Society for Maternal-Fetal Medicine (SMFM), Combs A, Kumar NR, Morgan JL, SMFM Patient Safety and Quality Committee. Society for Maternal-Fetal Medicine special statement: prophylactic low-dose aspirin for preeclampsia prevention-quality metric and opportunities for quality improvement. Am J Obstet Gynecol. 2023;229(2):B2\u20139. https:\/\/doi.org\/10.1016\/j.ajog.2023.04.039.","journal-title":"Am J Obstet Gynecol"},{"issue":"7","key":"682_CR25","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/aogs.13808","volume":"99","author":"P van Montfort","year":"2020","unstructured":"van Montfort P, et al. Low-dose-aspirin usage among women with an increased preeclampsia risk: a prospective cohort study. Acta Obstet Gynecol Scand. 2020;99(7):875\u201383. https:\/\/doi.org\/10.1111\/aogs.13808.","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"682_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0229622","volume":"15","author":"R Shanmugalingam","year":"2020","unstructured":"Shanmugalingam R, et al. Factors that influence adherence to aspirin therapy in the prevention of preeclampsia amongst high-risk pregnant women: a mixed method analysis. PLoS ONE. 2020;15(2):e0229622. https:\/\/doi.org\/10.1371\/journal.pone.0229622.","journal-title":"PLoS ONE"},{"issue":"5","key":"682_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajogmf.2022.100663","volume":"4","author":"DN Olson","year":"2022","unstructured":"Olson DN, Russell T, Ranzini AC. Assessment of adherence to aspirin for preeclampsia prophylaxis and reasons for nonadherence. Am J Obstet Gynecol MFM. 2022;4(5):100663. https:\/\/doi.org\/10.1016\/j.ajogmf.2022.100663.","journal-title":"Am J Obstet Gynecol MFM"},{"key":"682_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-023-06039-w","volume":"23","author":"N Singh","year":"2023","unstructured":"Singh N, Shuman S, Chiofalo J, Cabrera M, Smith A. Missed opportunities in aspirin prescribing for preeclampsia prevention. BMC Pregnancy Childbirth. 2023;23:717. https:\/\/doi.org\/10.1186\/s12884-023-06039-w.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"17","key":"682_CR29","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1056\/NEJMp2410855","volume":"391","author":"D Blumenthal","year":"2024","unstructured":"Blumenthal D, Gumas E, Shah A. The failing U.S. health system. N Engl J Med. 2024;391(17):1566\u20138. https:\/\/doi.org\/10.1056\/NEJMp2410855.","journal-title":"N Engl J Med"},{"key":"682_CR30","unstructured":"H. R. & S. A. Department of Health and Human Services (DHHS). Health Workforce Projections | Bureau of Health Workforce. https:\/\/bhw.hrsa.gov\/data-research\/projecting-health-workforce-supply-demand. Accessed 24 Sept 2025."},{"key":"682_CR31","doi-asserted-by":"publisher","DOI":"10.1515\/jpm-2025-0215","author":"JD Pozzo","year":"2025","unstructured":"Pozzo JD, et al. Implementation of a universal low-dose aspirin protocol for the prevention of preeclampsia in a federally qualified health center. J Perinat Med. 2025. https:\/\/doi.org\/10.1515\/jpm-2025-0215.","journal-title":"J Perinat Med"},{"issue":"2","key":"682_CR32","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1055\/a-2565-9272","volume":"43","author":"AR Kern-Goldberger","year":"2026","unstructured":"Kern-Goldberger AR, Sandhu K, Dolin CD, Bajan A, Raiff E, Lappen JR. The impact of universalizing aspirin prophylaxis on treatment provision for high-risk pregnant patients. Am J Perinatol. 2026;43(2):272\u20134. https:\/\/doi.org\/10.1055\/a-2565-9272.","journal-title":"Am J Perinatol"},{"issue":"10","key":"682_CR33","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.30960","volume":"4","author":"AK Lewkowitz","year":"2021","unstructured":"Lewkowitz AK, Rouse DJ. Miscommunication about low-dose aspirin for preeclampsia prevention\u2014further support for universal prophylaxis. JAMA Netw Open. 2021;4(10):e2130960. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.30960.","journal-title":"JAMA Netw Open"},{"key":"682_CR34","unstructured":"Introducing EncompassTM: a breakthrough solution from Mirvie to advance care for pregnancy complications. https:\/\/www.mirvie.com\/mirvie-media-releases\/introducing-encompass-a-breakthrough-solution-from-mirvie-to-advance-care-for-pregnancy-complications. Accessed 18 May 2026."},{"issue":"1","key":"682_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58157-y","volume":"16","author":"MA Elovitz","year":"2025","unstructured":"Elovitz MA, et al. Molecular subtyping of hypertensive disorders of pregnancy. Nat Commun. 2025;16(1):2948. https:\/\/doi.org\/10.1038\/s41467-025-58157-y.","journal-title":"Nat Commun"},{"issue":"10","key":"682_CR36","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s40273-015-0291-x","volume":"33","author":"N Zakiyah","year":"2015","unstructured":"Zakiyah N, Postma MJ, Baker PN, van Asselt ADI, On behalf of the IMPROvED Consortium. Pre-eclampsia diagnosis and treatment options: a review of published economic assessments. Pharmacoeconomics. 2015;33(10):1069\u201382. https:\/\/doi.org\/10.1007\/s40273-015-0291-x.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"682_CR37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. Value Health. 2012;15(6):796\u2013803. https:\/\/doi.org\/10.1016\/j.jval.2012.06.012.","journal-title":"Value Health"},{"issue":"1","key":"682_CR38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2012","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2012;17(1):5\u201314.","journal-title":"Value Health"},{"key":"682_CR39","unstructured":"US Census Bureau. Population projections. Census.gov. https:\/\/www.census.gov\/programs-surveys\/popproj.html. Accessed 07 Sept 2024."},{"issue":"7","key":"682_CR40","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377(7):613\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1704559.","journal-title":"N Engl J Med"},{"issue":"6","key":"682_CR41","doi-asserted-by":"publisher","first-page":"685.e1","DOI":"10.1016\/j.ajog.2017.08.110","volume":"217","author":"D Wright","year":"2017","unstructured":"Wright D, et al. Aspirin for evidence-based preeclampsia prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia. Am J Obstet Gynecol. 2017;217(6):685.e1-685.e5. https:\/\/doi.org\/10.1016\/j.ajog.2017.08.110.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"682_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041022","volume":"13","author":"B Demuth","year":"2024","unstructured":"Demuth B, Pellan A, Boutin A, Bujold E, Ghesqui\u00e8re L. Aspirin at 75 to 81 mg daily for the prevention of preterm pre-eclampsia: systematic review and meta-analysis. J Clin Med. 2024;13(4):1022. https:\/\/doi.org\/10.3390\/jcm13041022.","journal-title":"J Clin Med"},{"issue":"5","key":"682_CR43","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.jogc.2022.03.002","volume":"44","author":"LA Magee","year":"2022","unstructured":"Magee LA, et al. Guideline No. 426: Hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. J Obstet Gynaecol Can. 2022;44(5):547-571.e1. https:\/\/doi.org\/10.1016\/j.jogc.2022.03.002.","journal-title":"J Obstet Gynaecol Can"},{"issue":"S 1","key":"682_CR44","doi-asserted-by":"publisher","first-page":"e2410","DOI":"10.1055\/s-0043-1771260","volume":"41","author":"M Ayyash","year":"2024","unstructured":"Ayyash M, et al. Efficacy and safety of aspirin 162 mg for preeclampsia prophylaxis in high-risk patients. Am J Perinatol. 2024;41(S 1):e2410\u20137. https:\/\/doi.org\/10.1055\/s-0043-1771260.","journal-title":"Am J Perinatol"},{"issue":"1","key":"682_CR45","doi-asserted-by":"publisher","first-page":"101564","DOI":"10.1016\/j.ajogmf.2024.101564","volume":"7","author":"ME Jones Pullins","year":"2024","unstructured":"Jones Pullins ME, Boggess KA. Aspirin dose for preeclampsia prophylaxis: an argument for 162-mg dosing. Am J Obstet Gynecol MFM. 2024;7(1):101564. https:\/\/doi.org\/10.1016\/j.ajogmf.2024.101564.","journal-title":"Am J Obstet Gynecol MFM"},{"issue":"Suppl 1","key":"682_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ijgo.12802","volume":"145","author":"LC Poon","year":"2019","unstructured":"Poon LC, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: a pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet. 2019;145(Suppl 1):1\u201333. https:\/\/doi.org\/10.1002\/ijgo.12802.","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"682_CR47","doi-asserted-by":"publisher","first-page":"315.e1","DOI":"10.1016\/j.ajog.2024.06.038","volume":"232","author":"FH Amro","year":"2025","unstructured":"Amro FH, et al. Aspirin 162 mg vs 81 mg for preeclampsia prophylaxis in high-risk obese individuals: a comparative effectiveness open-label randomized trial (ASPREO). Am J Obstet Gynecol. 2025;232(3):315.e1-315.e8. https:\/\/doi.org\/10.1016\/j.ajog.2024.06.038.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"682_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12884-024-06397-z","volume":"24","author":"A Cowan","year":"2024","unstructured":"Cowan A, Haverty C, MacDonald R, Khodursky A. Impact of early preeclampsia prediction on medication adherence and behavior change: a survey of pregnant and recently-delivered individuals. BMC Pregnancy Childbirth. 2024;24(1):196. https:\/\/doi.org\/10.1186\/s12884-024-06397-z.","journal-title":"BMC Pregnancy Childbirth"},{"key":"682_CR49","unstructured":"Merative MarketScan\u00ae Commercial Claims Database (2019\u20132023). IBM Watson Health, Cambridge, MA. Data used under license."},{"key":"682_CR50","unstructured":"U.S. Bureau of Labor Statistics. Consumer price index: 2024 in review. 2025. Bureau of Labor Statistics (.gov)."},{"key":"682_CR51","doi-asserted-by":"crossref","unstructured":"Hamilton BE, Martin JA, Osterman MJK. Births: provisional data for 2023. https:\/\/stacks.cdc.gov. Accessed 17 Sept 2025.","DOI":"10.15620\/cdc\/151797"},{"issue":"6","key":"682_CR52","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1097\/AOG.0000000000003581","volume":"134","author":"J Hao","year":"2019","unstructured":"Hao J, et al. Maternal and infant health care costs related to preeclampsia. Obstet Gynecol. 2019;134(6):1227\u201333. https:\/\/doi.org\/10.1097\/AOG.0000000000003581.","journal-title":"Obstet Gynecol"},{"issue":"7","key":"682_CR53","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1038\/s41372-020-0635-z","volume":"40","author":"AL Beam","year":"2020","unstructured":"Beam AL, et al. Estimates of healthcare spending for preterm and low-birthweight infants in a commercially insured population: 2008\u20132016. J Perinatol. 2020;40(7):1091\u20139. https:\/\/doi.org\/10.1038\/s41372-020-0635-z.","journal-title":"J Perinatol"},{"issue":"7893","key":"682_CR54","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41586-021-04249-w","volume":"601","author":"M Rasmussen","year":"2022","unstructured":"Rasmussen M, et al. RNA profiles reveal signatures of future health and disease in pregnancy. Nature. 2022;601(7893):422\u20137. https:\/\/doi.org\/10.1038\/s41586-021-04249-w.","journal-title":"Nature"},{"issue":"1","key":"682_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-025-01332-9","volume":"27","author":"T Rajkumar","year":"2025","unstructured":"Rajkumar T, Hennessy A, Makris A. Remote blood pressure monitoring in pregnancies at risk of developing preeclampsia. Curr Hypertens Rep. 2025;27(1):15. https:\/\/doi.org\/10.1007\/s11906-025-01332-9.","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"682_CR56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ajog.2023.04.023","volume":"229","author":"JM Roberts","year":"2023","unstructured":"Roberts JM, et al. Care plan for individuals at risk for preeclampsia: shared approach to education, strategies for prevention, surveillance, and follow-up. Am J Obstet Gynecol. 2023;229(3):193\u2013213. https:\/\/doi.org\/10.1016\/j.ajog.2023.04.023.","journal-title":"Am J Obstet Gynecol"},{"key":"682_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.preghy.2019.12.001","volume":"19","author":"E Kalafat","year":"2020","unstructured":"Kalafat E, Benlioglu C, Thilaganathan B, Khalil A. Home blood pressure monitoring in the antenatal and postpartum period: a systematic review meta-analysis. Pregnancy Hypertens. 2020;19:44\u201351. https:\/\/doi.org\/10.1016\/j.preghy.2019.12.001.","journal-title":"Pregnancy Hypertens"},{"issue":"6","key":"682_CR58","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1097\/JHQ.0000000000000362","volume":"44","author":"A Burgess","year":"2022","unstructured":"Burgess A, Dalke K, Wheeling J, Clark K. Standardizing screening for preeclampsia risk factors to improve prescribing of low-dose aspirin. J Healthc Qual. 2022;44(6):324\u201330. https:\/\/doi.org\/10.1097\/JHQ.0000000000000362.","journal-title":"J Healthc Qual"},{"issue":"1","key":"682_CR59","doi-asserted-by":"publisher","first-page":"p. 651","DOI":"10.1186\/s12884-023-05922-w","volume":"23","author":"ME Gross","year":"2023","unstructured":"Gross ME, Godecker A, Hughes A, Sampene K. Leveraging quality improvement to promote health equity: standardization of prenatal aspirin recommendations. BMC Pregnancy Childbirth. 2023;23(1):651. https:\/\/doi.org\/10.1186\/s12884-023-05922-w.","journal-title":"BMC Pregnancy Childbirth"},{"issue":"6","key":"682_CR60","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1055\/s-0040-1718580","volume":"38","author":"RC Boelig","year":"2021","unstructured":"Boelig RC, Wanees M, Zhan T, Berghella V, Roman A. Improving utilization of aspirin for prevention of preeclampsia in a high-risk urban cohort: a prospective cohort study. Am J Perinatol. 2021;38(6):544\u201352. https:\/\/doi.org\/10.1055\/s-0040-1718580.","journal-title":"Am J Perinatol"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00682-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00682-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00682-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:48:37Z","timestamp":1791215317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00682-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":60,"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00682-7","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All analyses were conducted independently by TTi Health Research and Economics. Individual author disclosures: Susan Hahn is affiliated with Mirvie, Inc. April Zambelli-Weiner and Brian Nathanson are affiliated with TTi Health Research and Economics, which received funding from Mirvie to conduct this analysis.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The reportable data that support the findings of this study are included in the \u201cSupplemental Information\u201d (see the ESM). Other data are not publicly available, as the data were used under license from Merative MarketScan Commercial Claims database for the current study. Per the agreement with Merative MarketScan, raw data were deleted after their use. Data can be available upon request from Merative.","order":2,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":3,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":4,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not Applicable.","order":5,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The economic model is not publicly available but may be made available to reviewers upon reasonable request for evaluation purposes.","order":6,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AZW: Conceptualization; methodology; writing\u00a0\u2013 original draft; writing\u00a0\u2013 review and editing. BN: Formal analysis; writing\u00a0\u2013 review and editing. SH: Writing\u00a0\u2013 review and editing. All authors read and approved the final manuscript. All authors have reviewed and approved their disclosures, and all individuals have approved their acknowledgements.","order":7,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}